---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-052242"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2023-10-06T23:59:59+00:00"
generated_at: "2026-06-10T03:43:58.816233+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# FibroGen appoints Thane Wettig as permanent CEO and Board member, effective Oct 2, 2023

## Summary
- Thane Wettig promoted from Interim CEO to CEO and Board member as of Oct 2, 2023.
- Mr. Wettig had served as Interim CEO since July 23, 2023.
- Appointed as Class I director with term expiring at 2024 annual meeting.
- Compensation terms remain per prior 8-K filed July 25, 2023.

## SEC filing metadata
- accession: 0000950170-23-052242
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2023-10-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017023052242/0000950170-23-052242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017023052242/fgen-20231002.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-052242
- JSON: https://secwatch.observer/filing/0000950170-23-052242.json
- Plain text: https://secwatch.observer/filing/0000950170-23-052242.txt

## Key facts
- Executive change
  Thane Wettig was appointed as Chief Executive Officer at KYNTRA BIO, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On October 2, 2023, the Board of Directors (the “Board”) of FibroGen, Inc. (the “Company”) appointed Interim Chief Executive Officer Thane Wettig as (i) Chief Executive Officer and (ii) a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017023052242/0000950170-23-052242-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.